Global Stem Cell/Cord Blood Banking Market Report 2022: By Cell Type, Service, Bank Type and Application –


DUBLIN–(BUSINESS WIRE)–The report “Stem Cell/Cord Blood Banking Global Market Report 2022” has been added to from offer.

The global stem cell/cord blood banking market is expected to grow from $9.38 billion in 2021 to $10.23 billion in 2022 at a CAGR of 9%. The market is expected to reach $14.44 billion in 2026 with a CAGR of 9%.

The increase in the number of cancer patients is a major driver for the stem cell/cord blood banking market. Cancer diseases such as leukemia and multiple myeloma can be treated with stem cell transplantation. In stem cell transplantation, the treatment can be done either by autologous transplant in which the stem cells come from the same person who receives the transplant or by allogeneic transplant in which the stem cells come from a related or unrelated donor. By using stem cells in the treatment of cancer, hematopoietic stem cells that are damaged during chemotherapy can be restored. According to the American Cancer Society, in 2019, approximately 606,880 deaths were caused in the United States due to the prevalence of cancer which can be treated by transplanting stem cells.

Lack of awareness, especially among pregnant women, is a major barrier for the stem cell/cord blood banking market. This is mainly due to the fact that a majority of pregnant women do not know how public cord blood banks work. Therefore, this option is not fully explored despite the benefits of stem cell transplantation in the treatment of cancer. For example, according to the International Journal of Reproduction, Contraception, Obstetrics and Gynecology survey, only 45% of pregnant women knew about the use of umbilical cord blood during pregnancy, only 5% knew the cost of cord blood. intervention and less than 1% were aware of the availability of cord blood banks.

Pairing cord blood and tissue storage with genetic testing services is an emerging trend in the stem cell/cord blood banking market. Such pairing is possible and effective because of its complementary services to existing customers, helping to expand their product portfolio. For example, genetic testing company Natera launched the Evercord cord blood and tissue storage service that allows expectant parents to collect, store and potentially retrieve their newborn’s blood and cord tissue for medical purposes. therapeutics in transplantation and regenerative medicine applications.

The United States Food and Drug Administration (FDA) issues guidelines for stem cell/cord blood banking pursuant to Section 212 of the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121). Under this law, cord blood stem cells for unrelated allogeneic use are regulated by the FDA, and in order to distribute these products, distributors must obtain a license from the FDA. These licenses are issued by the FDA after examination of the manufacturing and storage conditions. In this regard, the American Association of Blood Banks and other regulatory bodies are also working with the FDA. Thus, the regulatory scenario related to Stem Cell/Cord Blood Banking market is expected to control the companies involved in this market.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market.

  • It traces historical and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.

  • The market size section gives the market size (in billions of dollars) covering both the historical market growth, the impact of the COVID-19 virus and the forecast of its recovery.

  • Market segmentations break down the market into sub-markets.

  • The regional and country breakdowns section gives an analysis of the market in each geography and the market size by geography and compares their historical and forecast growth.

  • It covers the impact and recovery trajectory of COVID-19 for all regions, major developed countries and major emerging markets.

  • The competitive landscape gives a description of the competitive nature of the market, market shares and a description of the major companies.

  • The main financial transactions that have shaped the market in recent years are identified.

  • The trends and strategies section analyzes the shape of the market coming out of the crisis and suggests how companies can grow as the market recovers.


Covered markets:

1) By cell type: adult stem cells; umbilical cord blood stem cells; Embryonic stem cells

2) Per Service: Collection; Treatment; Analysis; Storage

3) By type of bank: Public; Private

4) By application: leukemia; Anemia; Thalassemia; Autism; cerebral palsy ; Diabetes; Others

Data segmentation: historical and forecast national and regional data, competitor market share, market segments.

Companies mentioned

  • AMAG Pharmaceutical

  • Cordlife

  • Cryo-Cell International

  • hope

  • US Registry LLC

  • Chinese Cord Blood Society

  • Cordlife Group Limited

  • CordVida


  • Cryogenic stem cell

  • life cell

  • Perkin Elmer

  • Reelabs

  • International smart cells

  • Stemade Biotech

  • StemCyte

  • ViaCord

  • America

  • Life Cell International

  • Cryoviv India

  • Cytori therapeutics

  • Thermo Fisher Scientific

  • Cord Blood America Inc.

  • Stem Cyte

  • Aldagen

  • arteriocyte

  • Cell Therapy Brainstorming

For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.


Comments are closed.